Erfahrungsheilkunde 2020; 69(05): 252-259
DOI: 10.1055/a-1250-7161
Wissen

Misteltherapie in der Onkologie – Update der aktuellen Forschungsergebnisse

Friedemann Schad

Zusammenfassung

Mistelpräparate finden seit über 100 Jahren Anwendung in der Tumortherapie und sind im deutschsprachigen Raum nach wie vor die am häufigsten eingesetzten Arzneimittel in der integrativen Onkologie. Sie werden sowohl adjuvant als auch palliativ, meist in Kombination mit konventionellen Therapieverfahren angewandt und dienen in erster Linie zur Verminderung der durch diese Therapien bedingten Nebenwirkungen, der Verbesserung der Lebensqualität sowie der Reduktion tumorbedingter Symptome. In manchen Fällen kann auch eine direkte Tumorhemmung oder Tumorreduktion beobachtet werden. Einige Studien weisen auch auf eine Verlängerung des Gesamtüberlebens durch die Misteltherapie hin.

Zur Misteltherapie liegt eine Vielzahl an präklinischen und klinischen Studien vor. In dieser Übersicht wird die klinische Wirksamkeit anhand der aktuellen Studienlage und systematischen Reviews bzw. Metaanalysen besprochen. Außerdem werden Möglichkeiten einer Kombination mit gängigen Onkologika aufgezeigt.

Abstract

Mistletoe preparations have been used in cancer therapy for more than 100 years and are still the most frequently used medicinal products in integrative oncology in German-speaking countries. They are used in adjuvant and palliative situations, mostly in combination with conventional therapies. Their primary aim is to reduce the side effects caused by these therapies, to improve health-related quality of life and to reduce cancer-related symptoms. In some cases, direct tumour inhibition or tumour reduction can also be observed. In addition, several studies indicate an involvement of mistletoe in prolongation of overall survival.

A large number of preclinical and clinical studies on mistletoe therapy exist. In this overview, clinical efficacy is discussed on the basis of the current study situation and systematic reviews or meta-analyses. Possibilities of a combination with common oncological drugs are also demonstrated.



Publication History

Article published online:
16 October 2020

© MVS Medizinverlage Stuttgart GmbH & Co. KG
Stuttgart · New York

 
  • Literatur

  • 1 Selg P. Mensch und Mistel. Die Begründung der onkologischen Viscum-Behandlung durch Rudolf Steiner und Ita Wegman. Band 1. Berlin: Salumed; 2016: 1917-1925
  • 2 Büssing A. Mistletoe. The Genus Viscum. Amsterdam: Hardwood Academic; 2000
  • 3 Kienle GS, Kiene H. Die Mistel in der Onkologie: Fakten und konzeptionelle Grundlagen. Stuttgart: Schattauer; 2003
  • 4 Saller R, Reichling J, Melzer J. Misteltherapie – Erwünschte und unerwünschte Wirkungen in der wissenschaftlichen Diskussion, Teil 1. Praxismag 2004; 6-15
  • 5 Urech K, Scher JM, Hostanska K. et al. Apoptosis inducing activity of viscin, a lipophilic extract from Viscum album L. J Pharm Pharmacol 2005; 57: 101-109
  • 6 Urech K, Schaller G, Jäggy C. Viscotoxins, mistletoe lectins and their isoforms in mistletoe (Viscum album L.) extracts Iscador. Arzneimittelforsch 2006; 56: 428-434
  • 7 Urech K, Baumgartner S. Chemical constituents of Viscum album L.: Implications for the pharmaceutical preparation of mistletoe. Mistletoe – From mythology to evidence-based medicine. Transl Res Biomed Basel 2015; 11-23
  • 8 Nazaruk J, Orlikowski P. Phytochemical profile and therapeutic potential of Viscum album L. Nat Prod Res 2016; 30: 373-385
  • 9 Urech K, Jäggy C, Schaller G. Räumliche und zeitliche Dynamik der Viscotoxin- und Mistellektingehalte in der Mistel (Viscum album L.). In: Scheer R, Alban S, Becker H. et al., Hrsg. Die Mistel in der Tumortherapie 2. Essen: KVC; 2009: 67-77
  • 10 Braedel-Ruoff S. Immunomodulatory effects of Viscum album extracts on natural killer cells: Review of clinical trials. Forsch Komplementmed 2010; 17: 63-73
  • 11 Büssing A, Azhari T, Ostendorp H. et al. Viscum album L. extracts reduce sister chromatid exchanges in cultured peripheral blood mononuclear cells. Eur J Cancer 1994; 30 A: 1836-1841
  • 12 Büssing A, Regnery A, Schweizer K. Effects of Viscum album L. on cyclophosphamide-treated peripheral blood mononuclear cells in vitro: Sister chromatid exchanges and activation/proliferation marker expression. Cancer Lett 1995; 94: 199-205
  • 13 Büssing A, Jungmann H, Suzart K. et al. Suppression of sister chromatid exchange-inducing DNA lesions in cultured peripheral blood mononuclear cells by Viscum album L. J Exp Clin Cancer Res 1996; 15: 199-205
  • 14 Heiny BM, Beuth J. Mistletoe extract standardized for the galactoside-specific lectin (ML-I) induces beta-endorphin release and immunopotentiation in breast cancer patients. Anticancer Res 1994; 14: 1339-1342
  • 15 Büssing A, Suzart K, Bergmann J. et al. Induction of apoptosis in human lymphocytes treated with Viscum album L. is mediated by the mistletoe lectins. Cancer Lett 1996; 99: 59-72
  • 16 Büssing A, Schietzel M. Apoptosis-inducing properties of Viscum album L. extracts from different host trees correlate with their content of toxic mistletoe lectins. Anticancer Res 1999; 19: 23-28
  • 17 Janssen O, Scheffler A, Kabelitz D. In vitro effects of mistletoe extracts and mistletoe lectins. Cytotoxicity towards tumor cells due to the induction of programmed cell death (apoptosis). Arzneimittelforsch 1993; 43: 1221-1227
  • 18 Büssing A, Schaller G, Pfüller U. Generation of reactive oxygen intermediates (ROI) by the thionins from Viscum album L. Anticancer Res 1998; 18: 4291-4296
  • 19 Büssing A, Vervecken W, Wagner M. et al. Expression of mitochondrial Apo2.7 molecules and caspase-3 activation in human lymphocytes treated with the ribosome-inhibiting mistletoe lectins and the cell membrane permeabilizing viscotoxins. Cytometry 1999; 37: 133-139
  • 20 Schad F, Debus M, Soldner G. et al. Die Misteltherapie in klinischen Studien. https://www.mistel-therapie.de/wissenschaftliche-informationen/klinische-evidenz/klinische-studien Stand: 8.9.2020
  • 21 Büssing A, Raak C, Ostermann T. Quality of life and related dimensions in cancer patients treated with mistletoe extract (Iscador): A meta-analysis. Evid Based Compl Alt Med 2012; 219402
  • 22 Kienle GS, Kiene H. Influence of Viscum album L. (European mistletoe) extracts on quality of life in cancer patients: A systematic review of controlled clinical studies. Integr Cancer Ther 2010; 9: 142-157
  • 23 Loef M, Walach H. Quality of life in cancer patients treated with mistletoe: A systematic review and meta-analysis. BMC Compl Med Ther 2020; 20: 227
  • 24 Matthes H. Die Misteltherapie in der Onkologie – ein Update. Praxis Mag 2017; 9: 6-14
  • 25 Paepke D. Die Mistel in der Onkologie. Im Fokus Onkol 2018; 21: 64-68
  • 26 Tröger W, Jezdic S, Zdrale Z. et al. Quality of life and neutropenia in patients with early stage breast cancer: A randomized pilot study comparing additional treatment with mistletoe extract to chemotherapy alone. Breast Cancer 2009; 16: 35-45
  • 27 Tröger W, Galun D, Reif M. et al. Quality of life of patients with advanced pancreatic cancer during treatment with mistletoe: A randomized controlled trial. Dtsch Arztebl Int 2014; 111: 493-502
  • 28 Tröger W, Zdrale Z, Tisma N. et al. Additional therapy with a mistletoe product during adjuvant chemotherapy of breast cancer patients improves quality of life: An open randomized clinical pilot trial. Evid Based Compl Alt Med. 2014
  • 29 Friedel W E, Matthes H, Bock PR. et al. Systematic evaluation of the clinical effects of supportive mistletoe treatment within chemo- and/or radiotherapy protocols and long-term mistletoe application in nonmetastatic colorectal carcinoma: Multicenter, controlled, observational cohort study. J Soc Integr Oncol 2009; 7: 137-145
  • 30 Matthes H, Friedel WE, Bock PR. et al. Molecular mistletoe therapy: Friend or foe in established anti-tumor protocols? A multicenter, controlled, retrospective pharmaco-epidemiological study in pancreas cancer. Curr Mol Med 2010; 10: 430-439
  • 31 Schad F, Axtner J, Kröz M. et al. Safety of combined treatment with monoclonal antibodies and Viscum album L preparations. Integr Cancer Ther 2018; 17: 41-51
  • 32 Schad F, Thronicke A, Steele ML. et al. Overall survival of stage IV non-small cell lung cancer patients treated with Viscum album L. in addition to chemotherapy, a real-world observational multicenter analysis. PLoS One 2018; 13: e0203058
  • 33 Thronicke A, Oei SL, Merkle A. et al. Clinical safety of combined targeted and Viscum album L. therapy in oncological patients. Medic Basel 2018; 5
  • 34 Weissenstein U, Kunz M, Urech K. et al. Interaction of standardized mistletoe (Viscum album) extracts with chemotherapeutic drugs regarding cytostatic and cytotoxic effects in vitro. BMC Compl Alt Med 2014; 14: 6
  • 35 Weissenstein U, Kunz M, Urech K. et al. Interaction of a standardized mistletoe (Viscum album) preparation with antitumor effects of Trastuzumab in vitro. BMC Compl Alt Med 2016; 16: 271
  • 36 Weissenstein U, Kunz M, Oufir M. et al. Absence of herb-drug interactions of mistletoe with the tamoxifen metabolite (E/Z)-endoxifen and cytochrome P450 3A4/5 and 2D6 in vitro. BMC Compl Alt Med 2019; 19: 23
  • 37 Bock PR, Hanisch J, Matthes H. et al. Targeting inflammation in cancer-related-fatigue: A rationale for mistletoe therapy as supportive care in colorectal cancer patients. Inflamm Aller Drug Targ 2014; 13: 105-111
  • 38 Kröz M, Büssing A, Reif M. et al. Besteht eine Indikation für die Misteltherapie in der Behandlung von Cancer-related Fatigue und Insomnie bei Krebspatienten? Ein Review. In: Scheer R, Alban S, Becker H. et al., Hrsg. Die Mistel in der Tumortherapie 4 – Aktueller Stand der Forschung und klinische Anwendung. Essen: KVC; 2016: 287-298
  • 39 Wode K, Schneider T, Lundberg I. et al. Mistletoe treatment in cancer-related fatigue: A case report. Cases J 2009; 2: 77
  • 40 Elluru S, Huyen van JPD, Delignat S. et al. Tumor regressive effects of Viscum album perparations – Exploration of immunomodulatory mechanisms. Medicina 2007; 67: 85-89
  • 41 Schink M, Borowsky M. Zytotoxische Effekte von Mistellektinen und einem Mistelpräparat auf menschliche natürliche Killerzellen in vitro. In: Scheer R, Bauer R, Becker H. et al., Hrsg. Die Mistel in der Tumortherapie – Grundlagenforschung und Klinik. Essen: KCV; 2001: 163-176
  • 42 Simoes-Wüst P, Balthazar von L, Werner M. et al. Die Empfindlichkeit von Primärkulturen von Brustkrebszellen auf verschiedene Iscador-Präparate. In Scheer R, Alban S, Becker H. et al., Hrsg. Die Mistel in der Tumortherapie 3 – Aktueller Stand der Forschung und klinische Anwendung. Essen: KCV; 2013: 137-146
  • 43 Augustin M, Bock PR, Hanisch J. et al. Safety and efficacy of the long-term adjuvant treatment of primary intermediate- to high-risk malignant melanoma (UICC/AJCC stage II and III) with a standardized fermented European mistletoe (Viscum album L.) extract. Arzneimforsch 2005; 55: 38-49
  • 44 Grossarth-Maticek R, Ziegler R. Prospective controlled cohort studies on long-term therapy of breast cancer patients with a mistletoe preparation (Iscador). Forsch Komplementmed 2006; 13: 285-292
  • 45 Ostermann T, Raak F, Büssing A. Survival of cancer patients treated with mistletoe extract (Iscador): a systematic literature review. BMC Cancer 2009; 9: 451
  • 46 Ostermann T, Appelbaum S, Poier D. et al. A systematic review and meta-analysis on the survival of cancer patients treated with a fermented Viscum album L. extract (Iscador): An update of findings. Compl Med Res 2020. in press
  • 47 Tröger W, Galun D, Reif M. et al. Viscum album [L.] extract therapy in patients with locally advanced or metastatic pancreatic cancer: A randomised clinical trial on overall survival. Eur J Cancer 2013; 49: 3788-3797
  • 48 Axtner J, Steele M, Kröz M. et al. Health services research of integrative oncology in palliative care of patients with advanced pancreatic cancer. BMC Cancer 2016; 16: 579
  • 49 EudraCT-Nummer 2014–002386–30. Efficacy and safety of mistletoe extract in the palliative therapy of patients suffering from pancreatic cancer (PALM-Pan). https://www.clinicaltrialsregister.eu/ctr-search/search?query=PALM-Pan Stand: 13.9.2020
  • 50 EudraCT-Nummer 2014–004552–64. MISTRAL – Mistletoe therapy in primary and recurrent inoperable pancreatic cancer – A phase III prospective, randomized, double blinded, multicenter, parallel group, placebo controlled clinical trial. https://www.clinicaltrialsregister.eu/ctr-search/search?query=MISTRAL Stand: 13.9.2020
  • 51 Freuding M, Keinki C, Micke O. et al. Mistletoe in oncological treatment: A systematic review: Part 1: Survival and safety. J Cancer Res Clin Oncol 2019; 145: 695-707
  • 52 Freuding M, Keinki C, Micke O. et al. Mistletoe in oncological treatment: A systematic review. Part 2: Quality of life and toxicity of cancer treatment. J Cancer Res Clin Oncol 2019; 145: 927-939
  • 53 Matthes H, Thronicke A, Hofheinz RD. et al. Statement to an insufficient systematic review on Viscum album L. therapy. Hindawi Evidence-Based Complementary and Alternative Medicine Volume. 2020 Article ID 7091039, 9 pages
  • 54 Matthes H, Hofheinz RD, Bar-Sela G. et al. Letter to the editors of the Journal of Cancer Research and Clinical Oncology. J Cancer Res Clin Oncol 2019; 145: 2405-2407
  • 55 Tröger W, Zdrale Z, Stankovic N. et al. Five-year follow-up of patients with early stage breast cancer after a randomized study comparing additional treatment with Viscum album (L.) extract to chemotherapy alone. Breast Cancer Basic Clin Res 2012; 1: 173-180
  • 56 Tröger W, Zdrale Z, Stankovic N. Fünf-Jahres-Nachbeobachtung von Patientinnen mit Brustkrebs nach einer randomisierten Studie mit Viscum album (L.) Extrakt. Dt Z Onkol 2016; 48: 105-110
  • 57 Loewe-Mesch A, Kuehn JJ, Borho K. et al. Adjuvant simultaneous mistletoe chemotherapy in breast cancer – influence on immunological parameters, quality of life and tolerability. Forsch Komplementmed 2008; 15: 22-30
  • 58 Mansky PJ, Wallerstedt DB, Sannes TS. et al. NCCAM/NCI phase 1 study of mistletoe extract and gemcitabine in patients with advanced solid tumors. Ev-Bas Compl Altern Med 2013; 964592
  • 59 Thronicke A, Steele M L, Grah C. et al. Clinical safety of combined therapy of immune checkpoint inhibitors and Viscum album L. therapy in patients with advanced or metastatic cancer. BMC Compl Altern Med 2017; 17: 534
  • 60 Bundesinstitut für Arzneimittel und Medizinprodukte. NIS-Nr. 7049. Erste Teilstudie zur Anthroposophischen Komplextherapie (PHOENIX III) – Fallserie zur Vertiefung bzw. Gewinnung von Erkenntnissen zu bekannten bzw. bisher unbekannten unerwünschten Arzneimittelwirkungen und Wechselwirkungen unter routinemäßiger gemeinsamer Therapie von Immuncheckpoint-(PD-1, PD-L1, CTLA-4-)Inhibitoren mit Viscum album L.-Extrakten bei Patienten mit fortgeschrittenem nichtkleinzelligem Lungenkarzinom (Stadium IV nach UICC). https://awbdb.bfarm.de/ords/f?p=101:20::SET_SESSION_SCREEN_READER_ON Stand: 13.9.2020